AbbVie Inc.
AbbVie Appoints New Senior Vice President, Controller
Summary
On December 11, 2024, AbbVie Inc. announced that Kevin K. Buckbee, Senior Vice President, Controller, will retire effective March 1, 2025. David R. Purdue, who has held various finance roles at AbbVie and Abbott Laboratories since 2003, has been appointed to succeed him. Purdue's annual base salary will be $550,000, with an additional target bonus of 85% of his base salary, contingent on achieving performance targets.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement